# A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC

> **NCT05884398** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Janssen Research & Development, LLC** · enrollment: 420 (actual)

## Conditions studied

- Metastatic Castrate-sensitive Prostate Cancer

## Interventions

- **DRUG:** Apalutamide
- **DRUG:** Androgen-deprivation Therapy (ADT)

## Key facts

- **NCT ID:** NCT05884398
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-08-31
- **Primary completion:** 2026-10-12
- **Final completion:** 2028-10-12
- **Target enrollment:** 420 (ACTUAL)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05884398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05884398, "A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05884398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*